Press Releases

Date Title
Jul 18, 2023 Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
Jul 18, 2023 The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck
Jul 11, 2023 Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery
Jun 11, 2023 Illumina announces CEO transition plan
Jun 5, 2023 Illumina releases 2022 Corporate Social Responsibility Report
Jun 2, 2023 Illumina's Board of Directors elects two experienced Independent Directors to Board
Jun 1, 2023 Illumina unveils AI software to predict disease-causing genetic mutations in patients
May 31, 2023 Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023
May 30, 2023 Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing
May 25, 2023 Illumina announces preliminary results of annual meeting
May 18, 2023 Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees
May 16, 2023 Illumina's genomic technologies enable better pathogen preparedness and response
May 15, 2023 Illumina sends letter to shareholders detailing why Illumina's nominees far outmatch Icahn's slate in skills and experience
May 12, 2023 Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote "FOR" Eight of Illumina's Highly Qualified Director Nominees
May 8, 2023 Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's "Plan"
May 2, 2023 Illumina increases equitable access to STEM education, reaching over 1 million learners
May 1, 2023 Illumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card
Apr 25, 2023 Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth
Apr 20, 2023 Illumina Urges Shareholders to Vote the WHITE Proxy Card FOR all Nine of Illumina's Nominees
Apr 12, 2023 Illumina's cloud-based informatics programs recognized for robust, international data privacy protections
Apr 11, 2023 Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients
Apr 5, 2023 Illumina celebrates 25 years of innovation
Apr 4, 2023 Illumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023
Apr 4, 2023 Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023
Apr 3, 2023 Illumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024
Mar 30, 2023 Illumina Files Preliminary Proxy, Urging Shareholders to Vote for Its Director Nominees and Withhold for Each Icahn Group Nominee
Mar 27, 2023 Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease
Mar 24, 2023 Illumina Issues Statement in Response to Carl Icahn's Letter
Mar 20, 2023 Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements
Mar 14, 2023 Illumina launches its first product enabling long- and short-read sequencing on one instrument
Mar 13, 2023 Illumina Responds to Icahn Partners' Nomination of Directors
Mar 2, 2023 Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Feb 27, 2023 Illumina To Webcast Upcoming Investor Conference
Feb 8, 2023 Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute
Feb 7, 2023 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022
Feb 1, 2023 Illumina Appoints Joydeep Goswami Chief Financial Officer
Jan 10, 2023 Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
Jan 9, 2023 Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen